A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease
Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]
Elucidating the association between depression, anxiety, and cognition in middle-aged adults: Application of dimensional and categorical approaches
Background: In older adults, depressive and anxiety symptoms are associated with dementia risk, and represent a manifestation of the dementia prodrome. Understanding how these symptoms are related to cognition in midlife may inform risk models of […]
Building clinically relevant outcomes across the Alzheimer’s disease spectrum
Demonstrating that treatments are clinically meaningful across the Alzheimer’s disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer’s Association Research […]
Brain health registry GenePool study: A novel approach to online genetics research
Introduction Remote data collection, including the establishment of online registries, is a novel approach to efficiently identify risk for cognitive decline and Alzheimer’s disease (AD) in older adults, with growing evidence for feasibility and validity. Addition […]
Online study partner-reported cognitive decline in the Brain Health Registry
Introduction Methods for efficiently identifying cognitive decline and Alzheimer’s disease (AD) are a critical unmet need. The goal of this work was to validate novel online study partner (SP)-reported outcomes to identify cognitive decline in older […]
